

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application No.	10/670,179
Filing Date	September 23, 2003
First Named Inventor	Schochetman et al.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket No.	12636-796.301

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No. ¹	Document No.	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
SW		US-4,879,277	11-07-1989	Mitsuya et al.	
SW		US-5,422,344	06-06-1995	Priel et al.	
SW		US-5,622,959	04-22-1997	Priel et al.	
SW		US-5,641,773	06-24-1997	Pardee et al.	
SW		US-5,874,430	02-23-1999	Christ et al.	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
SW		WO 96/11005	04-18-1996	Leon T. ATLAS		
SW		WO 97/44492	11-27-1997	The Rockefeller University		


OTHER PRIOR ART - NON PATENT RELATED DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
SW		Carteau et al., "Effect of Topoisomerase Inhibitors on the <i>in vitro</i> HIV DNA Integration Reaction", Biochemical and Biophysical Research Communications, vol. 192, no. 3, pgs. 1409-1414, May 14, 1993.	
SW		Cimons, "Panel to Call for Triple-Drug Therapy for HIV Health: Federal Officials Seek to Reduce Confusion Among Doctors", Los Angeles Times (Home Edition), pg. A-18, Thursday, June 19, 1997.	
SW		Dornadula et al., "Residual HIV-1 RNA in Blood Plasma of Patients Taking Suppressive Highly Active Antiretroviral Therapy", JAMA, vol. 282, no. 17, pgs. 1627-1632, November 3, 1999.	
EXAMINER SIGNATURE		G. Wang	DATE CONSIDERED
			12/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application No.	10/670,179
Filing Date	September 23, 2003
First Named Inventor	Schochetman et al.
Art Unit	1614
Examiner Name	Unassigned
Attorney Docket No.	12636-796.301

Sheet

2

of

2

OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher city and/or country where published	T ²
SW		Fesen et al., "Inhibitors of Human Immunodeficiency Virus Integrase", Proc. Natl. Acad. Sci. USA, vol. 90, pgs. 2399-2403, March 1993.	
		Finzi et al., "Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy", Science, vol. 278, pgs. 1295-1300, November 14, 1997.	
		Hazunda et al., "Inhibitors of Strand Transfer that Prevent Integration and Inhibit HIV-1 Replication in Cells", Science, vol. 287, pgs. 646-650, January 28, 2000.	
		Hung et al., "9-Nitrocamptothecin Inhibits HIV-1 Replication in Human Peripheral Blood Lymphocytes: A Potential Alternative for HIV-Infection/AIDS Therapy", Journal of Medical Virology, vol. 64, pgs. 238-244, 2001.	
		Kilby et al., "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of gp41-Mediated Virus Entry", Nature Medicine, vol. 4, no. 11, pgs. 1302-1307, November 1998.	
		Li et al., "Camptothecin Inhibits Tat-Mediated Transactivation of Type 1 Human Immunodeficiency Virus", The Journal of Biological Chemistry, vol. 269, no. 10, pgs. 7051-7054, March 11, 1994.	
		Li et al., "Three Inhibitors of Type 1 Human Immunodeficiency Virus Long Terminal Repeat-Directed Gene Expression and Virus Replication", Proc. Natl. Acad. Sci. USA, vol. 90, pgs 1839-1842, March 1993.	
		Moulton et al., "9-Nitrocamptothecin Inhibits Tumor Necrosis Factor-Mediated Activation of Human Immunodeficiency Virus Type 1 and Enhances Apoptosis in a Latently Infected T Cell Clone", Aids Research and Human Retroviruses, vol. 14, no. 1, pgs. 39-49, 1998.	
		Oten et al., "Differential Replication and Pathogenic Effects of HIV-1 and HIV-2 in <i>Macaca nemestrina</i> ", AIDS, vol. 8, pgs. 297-306, 1994.	
		Pilcher et al., "Prolonged Therapy with the Fusion Inhibitor T-20 in Combination with Oral Antiretroviral Agents in an HIV-Infected Individual", AIDS, vol. 13, no. 15, pgs. 2171-2173, 1999.	
		Priel et al., "Inhibition of Human Immunodeficiency Virus (HIV-1) Replication in Vitro by Noncytotoxic Doses of Camptothecin, a Topoisomerase I Inhibitor", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 7, no. 1, pgs. 65-72, January 1991.	
		Sadaie et al., "9-Nitrocamptothecin Selectively Inhibits Human Immunodeficiency Virus Type 1 Replication in Freshly Infected Parental but Not 9-Nitrocamptothecin-Resistant U937 Monocytoid Cells", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 15, no. 3, pgs. 239-235, 1999.	
		Stephenson, "Studies Reveal Early Impact of HIV Infection, Effects of Treatment", JAMA Medical News & Perspectives[online], vol. 279, no. 9, March 4, 1998. (Retrieved 12/28/2001 from the Internet: <URL: http://www.ama-assn.org/special/hiv/newsline/special/jama/jmn80016.htm >.)	
		Takahashi et al., "Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Enhancement of Activity by Interaction with Cellular Topoisomerase I", Proc. Natl. Acad. Sci. USA, vol. 92, pgs. 5694-5698, June 1995.	
SW		Zhang et al., "Topotecan Inhibits Human Immunodeficiency Virus Type 1 Infection Through a Topoisomerase-Independent Mechanism in a Cell Line with Altered Topoisomerase I", Antimicrobial Agents and Chemotherapy, vol. 41, no. 5, pgs. 977-981, May 1997.	
EXAMINER SIGNATURE	S. Wang	DATE CONSIDERED	12/16/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

2755346_1.DOC

Attorney Docket No. 12636-796.601 (Appln. No. 10/670,179)